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Four rhesus macaques were sequentially immunized with live vaccines DvpuDnefSHIV-4 (vaccine-I) and Dvpu SHIVPPC
(vaccine-II). The vaccine viruses did not replicate productively in the peripheral blood mononuclear cells (PBMCs) of the
vaccinated animals. All four animals developed binding antibodies against both the vaccine-I and -II envelope glycoproteins
but neutralizing antibodies only against vaccine-I. They developed vaccine virus-specific CTLs that also recognized homol-
ogous as well as heterologous pathogenic SHIVs. Thirty weeks after the last immunization, the vaccinated animals and three
unvaccinated control animals were challenged iv with a highly virulent heterologous SHIV89.6P. As expected, the three
unvaccinated control animals developed large numbers of infectious PBMCs, high plasma viremia, and precipitous loss of
CD41 T cells. Two controls did not develop any immune response and succumbed to AIDS in about 6 months. The third
control animal developed neutralizing antibodies and had a more chronic disease course, but eventually succumbed to
AIDS-related complications 81 weeks after inoculation. The four vaccinated animals became infected with challenge virus as
indicated by the presence of challenge virus-specific DNA in the PBMCs and RNA in plasma. However, virus in these animals
replicated approximately 200- to 60,000-fold less efficiently than in control animals and eventually, plasma viral RNA became
undetectable in three of the four vaccinates. The animals maintained normal CD41 T-cell levels throughout the observation
period of 85 weeks after a transient drop at Week 3 postchallenge. They also maintained CTL responses throughout the
observation period. These studies thus showed that the graded immunization schedule resulted in a safe and highly effective
long-lasting immune response that was associated with protection against AIDS by highly pathogenic heterologous SHIV89.6P.
© 2001 Academic Press
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HIV-1 is not known to induce protective immunity
among any infected individuals, yet some persistently
infected individuals remain healthy and develop vastly
reduced virus concentrations in plasma [long-term non-
progressors (LTNP)] accompanied by humoral and cel-
lular immune responses to the virus, including neutraliz-
ing antibodies (Cao et al., 1995; Montefiori et al., 1996;
ilgrim et al., 1997; Binley et al., 1998; Zhang et al., 1997;
arotenuto et al., 1998; Cecilia et al., 1999) and CTLs
Betts et al., 1999; Bariou et al., 1997; Pontesilli et al.,
997; Harrer et al., 1996; Pilgrim et al., 1997; Klein et al.,
995; Nehete et al., 1998; Dyer et al., 1999). This obser-
ation suggested that an anti-HIV vaccine that can in-
Results of this study were presented at the XIIIth International AIDS
Conference, Durban, South Africa, July 9–14, 2000 (Abstract No.
TuPpA1223).a
s
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241uce this type of immune response and maintain it for a
rolonged period may be protective against AIDS follow-
ng exposure to HIV-1. Clinical trials currently in progress
re assessing the type and duration of immune re-
ponses that can be induced by recombinant proteins of
he virus (Graham and Wright, 1995; Graham et al., 1996;
ascola et al., 1996; Connor et al., 1998; Corey et al.,
998). However, in view of the tropism of the virus for the
efense/immune cells of the host, and that these cells
eside throughout the body, including mucosal surfaces,
t is unlikely that a vaccine would prevent infection fol-
owing exposure to the virus. Rather, success of the
accine would be assessed by its ability to limit spread
f the virus among the target cells and, hopefully, cause
limination of the infected cells. Since HIV causes fatal
nfections in humans, a comprehensive analysis of vac-
ine possibilities can be obtained only by use of animal
odels (Letvin, 1998).
The macaque models of HIV pathogenesis using SIVnd SHIV provide the best systems to assess vaccine
afety and efficacy (Hirsch et al., 1995; Luciw et al., 1995;
0042-6822/01 $35.00
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242 KUMAR ET AL.Joag et al., 1996, 1997; Reimann et al., 1996a,b; Igarashi
t al., 1999). The SIV model has provided seminal infor-
ation in the vaccine field. For example, this model has
hown that use of inactivated virus preparations and
ecombinant viral proteins as vaccines were controver-
ial, if not of equivocal value, in protection against dis-
ase (Murphey-Corb et al., 1989; Cranage et al., 1992;
ohnson et al., 1992; Langlois et al., 1992; Putkonen et al.,
993; Daniel et al., 1994). The model has also shown that
eletion of accessory genes from pathogenic SIV re-
ulted in attenuation of the virulence of the agent and,
urther, that use of such attenuated viruses as vaccines
esulted in induction of protection against disease
aused by pathogenic strains of virus. In nearly all cases,
rotection was associated with development of cytotoxic
ntiviral CD81 T cells (Johnson et al., 1997, 1999; Joag et
al., 1998a; Johnson and Desrosiers, 1998; Wyand et al.,
999), the same type of cells seen in human HIV-infected
TNP (Harrer et al., 1996; Nehete et al., 1998). The effec-
tiveness of the CD81 T cells was previously proven with
the demonstration that elimination of these cells from
animals resulted in enhanced virus replication (Schmitz
et al., 1999; Jin et al., 1999). The major problem involving
use of the gene-deleted attenuated SIV vaccine is the
retention of virulence of the virus. In a recent study, live
attenuated SIV, when inoculated to newborn macaques,
became pathogenic (Baba et al., 1999).
The SHIV model was developed after establishment of
the SIV model but its use supported findings made using
the SIV model, with the demonstration that live attenuated
vaccines were highly effective in preventing disease (Joag
et al., 1998a). These live attenuated vaccines were con-
structed based on our observations that the two accessory
genes vpu and nef were important for virulence, as evident
by expression of functional Vpu protein and several
changes in the nef gene in pathogenic SHIVKU that was
erived from nonpathogenic SHIV-4 (McCormick-Davis et
l., 1998). Assuming that changes in the two accessory
enes vpu and nef contributed to the development of a
virulent virus variant, we deleted portions of both genes
from the original SHIV-4 virus and designated this virus
DvpuDnefSHIV-4 (vaccine-I). We also selected another non-
pathogenic virus (SHIVPPC) and deleted 60 bp in the vpu
gene and designated that as DvpuSHIVPPC (vaccine-II).
Use of both SIV and SHIV vaccines showed that pro-
ection correlates with the degree of replication of the
accine virus (Johnson et al., 1999). The less the virus
eplicated, the less effective it was in eliciting protection.
n the other hand, the more the vaccine virus replicates,
he greater the chance that it would be pathogenic. The
est vaccine would therefore be one that replicated
inimally yet be highly effective in inducing protective
mmunity. In an earlier report, we confirmed the replica-
ion/efficacy concept with use of the two SHIV vaccines.
he first vaccine, vaccine-I, replicated minimally but, al-
hough disease caused by challenge virus, SHIVKU, wasdelayed, five of six immunized animals eventually devel-
oped AIDS. In contrast, the second vaccine, vaccine-II,
replicated robustly with demonstrable infectivity in PB-
MCs but without causing pathological effects. The pro-
ductive infection, however, was transient. It was highly
effective in preventing AIDS. All of the animals immu-
nized with this virus became infected with the challenge
virus but the challenge virus became unrecoverable from
five of the six animals and all six have remained healthy
for more than 3 years. Success of vaccine-II was as-
cribed to cellular and humoral immune responses in-
duced by the vaccine virus during the productive phase
of replication (Silverstein et al., 2000).
In the experiments described in this report, we asked
whether animals immunized sequentially with vaccine-I
and vaccine-II (graded immunizations) would result in re-
duced productive replication of vaccine-II but with the same
beneficial effects of vaccine-II (complete protection against
AIDS) that was associated with the productive replication of
this virus when given alone. The purpose of the present
study was threefold: (1) to determine whether prior immu-
nization of macaques with vaccine-I would attenuate the
replication of vaccine-II, and thus reduce the potential for
the latter to become pathogenic; (2) to characterize the
immune responses to the vaccine viruses and the chal-
lenge virus following immunization, but prior to challenge;
and (3) to determine whether the immunized animals would
resist development of AIDS following exposure to the chal-
lenge virus and, if so, whether challenge virus concentra-
tions would decline with time, following anticipated infec-
tion at the time of exposure. We examined the cellular and
humoral immune responses in four rhesus macaques after
sequential immunization with vaccine-I followed by vac-
cine-II. These animals along with three unvaccinated con-
trol animals were challenged with highly pathogenic
SHIV89.6P that has an envelope that is antigenically distinct
from that of the vaccine viruses but shares the Gag and Pol
of the latter. Challenged vaccinated and unvaccinated ani-
mals were monitored for virus replication, clinical disease,
and longevity of immune responses for more than 19
months.
RESULTS
Vaccine phase
Four animals were administered vaccine-I, followed by
two sequential inoculations at 4 and 7 months with vaccine-
II. Infectious PBMCs were not detected at any time points in
any of the animals following each of the three vaccinations.
However, viral infection was established in all four animals,
as determined by amplification of SIVgag in PBMC DNA by
PCR showing a low level of replication that was undetect-
able by classical infectious cell assays. These animals did
not lose CD41 T cells (data not shown). Nevertheless, prior
immunization with vaccine-I was associated with reduced
replication of vaccine-II.
243IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSDevelopment of binding and neutralizing antibodies in
vaccinated macaques
Plasma samples were examined for binding and neu-
tralizing antibodies 9 weeks after the first vaccination, at
two time points (Weeks 19 and 26) 3 and 10 weeks after
oral inoculation with vaccine-II, and at three time points
(Weeks 38, 46, and 55) beginning 10 weeks after the
second vaccination with vaccine-II (Table 1). Vaccine-I
induced binding antibodies in only one of the four vac-
cinated animals (RPz). None developed neutralizing an-
tibodies against the virus. Three weeks after oral inocu-
lation with vaccine-II given at Week 16, all four animals
developed binding antibodies to vaccine-I and one de-
T
Binding and Neutralizing Antibody Titers against Vaccine a
with Vaccine-I (Week 0) an
Macaque
Week
p.i.
Vaccine
inoculation
Bin
Vac-I En
RJo 0 Vac-I ,100
9 ,100
16 Vac-II ND
19 2000
26 2000
28 Vac-II ND
38 8000
46 8000
55 8000
RPz 0 Vac-I ,100
9 500
16 Vac-II ND
19 1000
26 4000
28 Vac-II ND
38 16,000
46 16,000
55 16,000
RTt 0 Vac-I ,100
9 ,100
16 Vac-II ND
19 ,100
26 500
28 Vac-II ND
38 4000
46 4000
55 4000
RWg 0 Vac-I ,100
9 ,100
16 Vac-II ND
19 500
26 2000
28 Vac-II ND
38 8000
46 8000
55 8000
Note. ND, Not done.veloped detectable antibody against vaccine-II (RPz; an-
tibody titer 100). This response was boosted further afterthe third vaccination at Week 28, with development of an
anamnestic response to vaccine-I. The animals also de-
veloped low titers of neutralizing antibodies to vaccine-I
(peak antibody titer 20–40), but only after immunization
with vaccine-II. None developed neutralizing antibodies
to vaccine-II. The vaccine-I-specific antibodies did not
neutralize SHIV89.6P that was used for challenge.
Vaccinated animals developed CTLs that recognized
and lysed CD41 T cells infected with heterologous
challenge virus SHIV89.6P
We tested PBMCs, obtained 19 weeks after the last
immunization, for their potential to lyse autologous Her-
1
llenge Viruses in Four Macaques Immunized Sequentially
ine-II at Weeks 16 and 28
ntibody titer Neutralizing antibody titer
Vac-II Env Vac-I Vac-II 89.6P
,100 ,10 ,10 ,10
,100 ,10 ,10 ,10
ND ND ND ND
,100 40 ,10 ,10
,100 20 ,10 ,10
ND ND ND ND
4000 10 ,10 ,10
4000 40 ,10 ,10
4000 10 ,10 ,10
,100 ,10 ,10 ,10
,100 10 ,10 ,10
ND ND ND ND
100 20 ,10 ,10
500 10 ,10 ,10
ND ND ND ND
8000 20 ,10 ,10
4000 20 ,10 ,10
8000 40 ,10 ,10
,100 ,10 ,10 ,10
,100 ,10 ,10 ,10
ND ND ND ND
,100 ,10 ,10 ,10
100 ,10 ,10 ,10
ND ND ND ND
2500 20 ,10 ,10
2000 20 ,10 ,10
2000 20 ,10 ,10
,100 ,10 ,10 ,10
,100 ,10 ,10 ,10
ND ND ND ND
,100 ,10 ,10 ,10
1000 10 ,10 ,10
ND ND ND ND
8000 20 ,10 ,10
8000 10 ,10 ,10
8000 10 ,10 ,10ABLE 1
nd Cha
d Vacc
ding a
vpesvirus saimiri (HS)-immortalized CD4 T cells infected
with vaccine-II virus, homologous pathogenic virus
w
2
e
1
244 KUMAR ET AL.SHIVKU-2, and heterologous pathogenic virus SHIV89.6P.
The results of this experiment are shown in Fig. 1. The
effectors from all four vaccinates recognized all three
viruses and lysed the targets infected with them. As
expected, effectors from different macaques exhibited
different degrees of lysis, of which macaque RJo was the
FIG. 1. Lysis of vaccine-II- SHIVKU-2-, and SHIV89.6P-infected targets by
CTLs from vaccinated macaques induced by sequential immunization
with vaccine-I and vaccine-II. The CTL effectors were prepared from
the four vaccinated animals by cocultivation of PBMC, obtained 19
weeks after the third vaccine inoculation, with UV-irradiated autologous
HS CD41 T-cell clones infected with vaccine-II as described under
Materials and Methods. They were tested after 2 weeks of initial
stimulation against control T cells and autologous HS CD41 T-cell
clones infected with vaccine-II, SHIVKU-2, and SHIV89.6P. The effectors
ere tested in a 4-h chromium release assay at E/T ratio of 80/1, 40/1,
0/1, and 10/1. The results presented here depict specific lysis at a
ffector/target ratio of 40/1. The mean spontaneous lysis was between
56 and 668 and maximal release between 506 and 2143.best followed by RWg, RTt, and RPz, respectively. Gen-
erally, vaccine-II-specific lysis was highest, followed bySHIVKU-2 and SHIV89.6P. In view of the results that CTLs
from different vaccinated animals recognized two distinct
viruses that contained the envelopes from two different
isolates of HIV-1, we decided to analyze whether vac-
cine-induced CTLs were directed against only one pro-
tein or different proteins encoded by viruses.
We used the same CTL effectors and tested them
against autologous B-LCL targets infected with recom-
binant vaccinia viruses expressing either HIV-1Env,
SIV-Gag, or SIV-Pol. In another experiment, we ob-
tained lymph node biopsies at Week 19 following the
third immunization, and prepared single-cell suspen-
sions, stimulating them in a similar manner as done for
PBMC. These cells were used as lymph node effec-
tors, to determine whether CTLs were present in sec-
ondary lymphoid tissues. The results of these experi-
ments are illustrated in Fig. 2. Lymph node effectors
showed more pronounced lysis than that of PBMC
effectors. Surprisingly, all four vaccinated macaques
showed predominantly anti-Env-specific CTLs in the
lymph nodes, followed by Gag and Pol. In contrast,
PBMC effectors from each animal responded differ-
ently to the viral proteins, with macaque RJo showing
maximum lysis against Gag, RPz against Pol, and RTt
as well as RWg against Env. Interestingly, macaque
RWg PBMC effectors showed lysis only against Env.
However, those effectors recognized both SHIVKU and
SHIV89.6P (Fig. 2).
Challenge phase
Clinical outcome of SHIV89.6P infection in unvaccinated
control animals. Thirty weeks after the third immuniza-
tion, the four vaccinated and three unvaccinated animals
were challenged by iv inoculation of 1 ml of undiluted
SHIV89.6P (10,000 TCID50). The three unvaccinated control
animals developed highly productive infections (Figs. 3B
and 3C) and lost .90% CD41 T cells within 3 weeks (Fig.
3A). Two control animals (49/P1 and 49/P2) progressed
to clinical AIDS and were euthanized at Weeks 27 and
30, respectively. The third control (52/C) developed a
more chronic course of disease and succumbed to AIDS-
related complications at Week 81 postchallenge. Exam-
ination of viral burdens in these animals showed that all
three had equivalent viral RNA levels of approximately
107 copies Eq/ml at Week 2 and 5 3 105–5 3 106 be-
tween Weeks 2 and 16. However, these animals varied in
numbers of infectious cells in PBMC. The two rapid
progressors had much higher numbers of infectious PB-
MCs (1000 infected cells/106 PBMCs) compared to the
slow progressor (10 infected cells/106 PBMCs) (Fig. 3C).
These data suggested that the major site of virus repli-
cation in 52/C was in cells other than PBMC, and that the
free virus that was detected in real-time RT-PCR must
have been transported to plasma.
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245IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSClinical outcome of SHIV89.6P challenge in vaccinated
animals: viral loads in plasma. Viral loads in the four
vaccinated animals after challenge with SHIV89.6P were
uantified by monitoring viral RNA, presence of infec-
ious cells in PBMCs, and virus recovery from CD8-
epleted PBMCs and lymph node cells. Virus RNA was
etected in plasma of all four animals. The peak viral
oads in plasma were 230, 5700, 62,000, and 3100 copy
q/ml in macaque RJo, RPz, RWg, and RTt, respectively.
imilar to the control animals, the peak viral burden was
bserved 2 weeks after challenge. No infectivity was
etected in PBMCs of the animals. It is thus possible that
ither the virus was replicating in cells other than PB-
FIG. 2. CTL activities of PBMC and lymph node effectors against HIV
obtained 19 weeks after the third vaccine inoculation and the CTL eff
CD41 T-cell clones infected with vaccine-II as described under Materia
argets infected with wild-type vaccinia virus (—), and recombinant
(v—v). The effectors were tested in a 4-h chromium release assay a
experiments was between 153 and 650 and the mean maximal releasCs or that the infectious cell assay system was not
ensitive enough to detect the low levels of virus repli-cation. Viral RNA in plasma became undetectable in two
of the four vaccinates (RJo and RPz) by Week 4. These
animals remained virus-negative throughout the obser-
vation period of over 85 weeks. The two other vaccinated
animals followed a slightly different course of infection.
Macaque RTt showed peak viral burden of 3100 copy
Eq/ml. In the following weeks, the viral burden in this
animal ranged between 100 and 1000 copies of viral
RNA/ml of plasma until Week 52, when the virus load
declined below the level of detection (100 copies Eq/ml
plasma). However, at Week 77, when the last real-time
RT-PCR analysis was performed, the viral RNA load in
this animal was 630 RNA copies Eq/ml. The fourth vac-
SIV-Gag, and SIV-Pol proteins. The PBMC and lymph node cells were
were prepared by stimulating them with UV-irradiated autologous HS
ethods. The growing effectors were tested against autologous B-LCL
a viruses expressing HIV-1ENV (n —n ), SIV-GAG (—), and SIV-POL
tio of 80/1, 40/1, 20/1, and 10/1. The mean spontaneous lysis in these
between 587 and 2565.-1Env,
ectors
ls and M
vaccinicinated animal (RWg) was the least protected in terms of
intensity of virus replication. The virus continued to rep-
M
C
H
a
e
e
n
a
w
246 KUMAR ET AL.licate at a low level (2100–29,000 copy Eq/ml) until Week
69 postchallenge. However viral RNA was no longer
detectable in plasma of this animal beyond this point
(Fig. 4B).
Virus recovery from PBMCs and lymph nodes
Several experiments involving cocultivation of 106 PB-
Cs of the four challenged vaccinates with indicator
8166 cells failed to result in rescue of infectious virus.
owever, virus was recovered from PBMCs of two of the
nimals after depletion of CD81 T cells from the cell
suspensions. The virus rescue attempts were performed
using PBMC at Weeks 6, 16, 50, and 82 and lymph node
cells at Weeks 50 and 82. At Week 6, only two (RWg and
FIG. 3. CD41 T-cell profile (A), cell-associated virus load (B), and
plasma viral load (C) in the three unvaccinated control monkeys inoc-
ulated with SHIV89.6P. The CD4 profile was determined by a whole blood
lysis technique as described under Materials and Methods. The cell-
associated virus load is shown as number of infectious cells/106 PBMC
nd determined by infectious cell assay. The viral RNA load in plasma
as determined by real-time RT-PCR.RTt) of the four animals yielded infectious virus from
CD8-depleted cells. These results corroborated real-timeRT-PCR results that showed a low concentration of viral
RNA in plasma of only these two animals. These results
also suggested an important role for the CD81 T cells in
controlling virus replication. At Week 16 following chal-
lenge, only macaque RWg yielded virus from CD8-de-
pleted PBMCs, again supporting real-time RT-PCR exper-
iments. At Week 50, CD8-depleted PBMCs from different
animals did not yield virus. However, macaque RWg
harbored viral RNA in plasma. This suggested that infec-
tious virus may have been present in tissue compart-
ments other than PBMC. This was confirmed by virus
recovery from CD8-depleted LN cells from macaque
RWg at Week 50. CD8-depleted LN cells from the other
three vaccinates did not yield virus at this time. Further
analyses at Week 82 postchallenge showed that none of
the four animals yielded infectious virus from PBMC or
lymph nodes.
Persistence of challenge virus-specific DNA in PBMC
and lymph nodes
In the next series of experiments, we sought to deter-
mine whether viral DNA persisted in PBMCs and lymph
nodes at different time points after challenge. The results
of these experiments are shown in Fig. 5. The SHIV89.6P
DNA was present in PBMCs of all four animals 1 week
after challenge. At Week 50 only two animals (RWg and
RTt) had detectable viral DNA of this virus in PBMCs.
However, at this time three of the four animals (RWg, RPz,
and RTt) had detectable challenge virus-specific DNA in
peripheral lymph nodes. At Week 85 only RWg and RTt
had detectable SHIV89.6P-specific DNA in PBMCs and
lymph nodes.
After challenge with SHIV89.6P, the vaccinated animals
were also monitored for levels of CD41 T cells in blood.
Results of these experiments are shown in Fig. 4A. All
four animals showed a transient decrease in the levels of
CD41 T cells soon after challenge, but cell counts recov-
red to normal levels in three animals within 5 weeks. As
xpected, macaque RWg showed relatively more pro-
ounced CD41 T-cell loss, which was attributed to a
higher level of virus replication compared to that of other
animals.
Immune responses in vaccinated and control
macaques after challenge with SHIV89.6P:
humoral immune response
All four vaccinated animals developed anamnestic
neutralizing antibodies to vaccine-I virus during the first
8 weeks following challenge. The neutralizing-antibody
titers to this virus were maintained in all four vaccinated
animals throughout the observation period. None of the
four vaccinates developed detectable neutralizing anti-
bodies against vaccine-II virus but all four developed
neutralizing antibodies to SHIV89.6P. These became de-
tectable within 4 to 8 weeks after challenge. The anti-
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247IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSbody levels increased gradually and achieved peak lev-
els between Weeks 32 and 62 postchallenge. The
SHIV89.6P-specific neutralizing antibodies persisted
throughout the 85-week observation period (Table 2).
The two control animals (49/P1 and 49/P2) that devel-
oped disease within 7 months did not produce any neu-
tralizing antibodies to SHIV89.6P. The third control animal
(52/C) produced significant amounts of neutralizing anti-
bodies that were first detectable about 6 months post-
challenge. The antibodies persisted until the animal died
with AIDS (Table 3).
Vaccinated animals developed increased CTL activity
after challenge with SHIV89.6P
The unvaccinated animals did not develop any CTLs
against SHIV89.6P when tested 12 weeks after inoculation
with SHIV89.6P. PBMCs from the third control animal
52/C) that developed a chronic disease course also
ailed to develop CTLs when examined at Weeks 24 and
2 (data not shown). The PBMC effectors from four vac-
inated animals were tested at four time points for their
ytotoxic potential, starting from 12 weeks after chal-
enge with SHIV89.6P. At Week 12 postchallenge, cells
from three of the four animals caused increased lysis
FIG. 4. CD41 T-cell profile (A) and plasma viral load (B) in four vacci
and challenged with SHIV89.6P. The CD4 profile was determined by a who
as described under Materials and Methods.(E/T ratio of 40/1, Fig. 6) when compared to that obtained
before challenge (Figs. 1 and 2). The postchallenge CTLresponses of macaques RJo and RPz were directed pre-
dominantly to the Gag protein, with decreasing activity
against Pol and Env, respectively. The fourth macaque,
RWg, did not develop any significant increase in virus-
specific CTL activity after challenge. Interestingly, this
was the only macaque that was found to harbor virus in
the lymph nodes, 1 year postchallenge. Macaques RJo
and RPz, that had developed the most potent prechal-
lenge CTLs and showed increased activity after chal-
lenge, did not have detectable challenge virus DNA in
PBMC and lymph nodes. Note that increased CTL-medi-
ated lysis was not considered as anamnestic because of
in vitro manipulation of these cells. However, reduced
lysis by RWg effectors might have been responsible for
the least protection in this animal. Subsequently, all four
animals developed CTL activity against Env, Gag, and
Pol proteins and these activities were maintained
throughout the remainder of the observation period. We
also included Nef protein as a target at Weeks 52 and 77
postchallenge. All four animals showed significant lysis
against Nef (Table 4).
Vaccine-induced CTLs were CD81 T cells and MHC
restricted
nimals immunized sequentially with vaccine-I, followed by vaccine-II,
d lysis technique and the viral RNA load in plasma by real-time RT-PCRnated aVaccine-induced CTLs were characterized by testing
for CTL activity in CD41 and CD81 T-cell populations
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248 KUMAR ET AL.against syngenic and allogenic targets. Unfractionated
PBMCs and positively selected CD41 and CD81 T cells
rom vaccinated macaques were cocultured with irradi-
ted autologous HS CD41 T cells infected with SHIV89.6P.
fter 2 weeks of culture, the three cell populations were
sed as effectors in the chromium-release assay and
ested against autologous CD41 T cells infected with
SHIV89.6P. Unfractionated PBMC effectors were also
tested against allogenic targets infected with SHIV89.6P. A
CD41 T-cell clone from another rhesus macaque was
used as the allogenic target. The results of this experi-
ment are shown in Fig. 7. The effectors from all four
T
Postchallenge Neutralizing Antibody Titers against Vaccine and
with Vaccine-I and -II, and Chall
Week
postchallenge
RJo RPz
Vac-I Vac-II 89.6P Vac-I Vac-II
4 10 ,10 ,10 320 ,10
8 80 ,10 20 320 ,10
12 20 ,10 80 320 ,10
20 10 ,10 80 320 ,10
32 10 ,10 320 320 ,10
40 10 ,10 320 320 ,10
52 10 ,10 160 320 ,10
62 20 ,10 160 320 ,10
FIG. 5. PCR analyses of the viral sequences present in PBMCs and
lymph nodes of the four animals that were immunized with vaccine-I,
followed by vaccine-II, and challenged with SHIV89.6P. The 0.5-mg DNA
amples were amplified in seminested PCR using SHIV89.6P env-spe-
cific primers. The primers were specific for SHIV89.6P env as they did not
amplify vaccine env in a separate reaction.77 20 ,10 160 320 ,10macaques recognized and lysed autologous targets in-
fected with SHIV89.6P but not the allogenic targets in-
fected with the same virus, indicating that CTL activity
was MHC restricted. The CD81, but not the CD41, T-cell
fraction from PBMCs, when used as effectors, exhibited
CTL activity. This suggested that the CTLs developed by
these vaccinated animals were CD81 T cells (Fig. 7).
DISCUSSION
In our earlier studies, we showed that vaccine-II but
not vaccine-I conferred long-lasting protection against
SHIV-induced AIDS (Joag et al., 1998a; Silverstein et al.,
2000). However, the protective efficacy of vaccine-II was
associated with productive infection, albeit transiently, in
PBMCs. This was considered a potential for becoming
pathogenic. In the present study, the central question
was whether the vaccinated animals could benefit from
the immunization with vaccine-II in the absence of (po-
tentially dangerous) productive infection by the virus.
Therefore, we adopted a new immunization strategy con-
sisting of immunization first with the more-attenuated
virus (vaccine-I) followed by immunization with a less-
attenuated virus (vaccine-II), hoping that vaccine-I-in-
duced immune responses would suppress the replica-
tion of vaccine-II virus. The study showed clearly that all
four of the sequentially immunized animals failed to
develop infectious cells among their PBMCs following
exposure to vaccine-II. However, we could not rule out a
low level of replication that was not detectable by infec-
tious cell assays. The doubly immunized animals devel-
oped CTLs, but (as expected) no neutralizing antibodies
to the heterologous challenge virus. This was the state of
their immunity when at 30 weeks after the last exposure
to vaccine, the animals were challenged iv with a high
dose of SHIV89.6P. These animals became infected with
the challenge virus, but concentrations of the latter de-
creased progressively with time and became undetect-
nge Viruses in Vaccinated Macaques Immunized Sequentially
with Pathogenic Virus SHIV89.6P
lizing antibody titer
RTt RWg
.6P Vac-I Vac-II 89.6P Vac-I Vac-II 89.6P
40 20 ,10 40 160 ,10 40
40 20 ,10 20 320 ,10 40
40 20 ,10 40 320 ,10 160
80 10 ,10 160 160 ,10 320
60 20 ,10 160 320 ,10 320
60 10 ,10 320 320 ,10 320
60 10 ,10 320 160 ,10 320
40 20 ,10 640 160 ,10 640ABLE 2
Challe
enged
Neutra
89
1
1
140 20 ,10 640 160 ,10 640
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249IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSable in three of four vaccinates. The mechanism of pro-
tection in this study may be attributed to the presence of
CTL precursors at the time of exposure to the challenge
virus, rather than neutralizing antibodies, since these did
not develop until after the challenge virus had been
brought under control. Since vaccine-I had not induced
protective immunity in the earlier study (Joag et al.,
1998a), the protection observed in the present study was
TABLE 3
Neutralizing Antibody Titers against Challenge Virus in Three
Control Macaques Inoculated with Pathogenic SHIV89.6P
Week
postchallenge
Neutralizing antibody titer against
SHIV89.6P
49/P1 49/P2 52/C
4 ,10 ,10 ,10
8 ,10 ,10 ,10
12–13 ,10 ,10 ,10
16 ,10 ,10 ,10
20–21 ,10 ,10 ,10
25–30 ,10 ,10 20
33 320
42 80
53 320
65 640
77 320
FIG. 6. Postchallenge CTL activity of the vaccinated macaques agains
macaques, obtained 12 weeks after challenge with pathogenic virus S
lones infected with SHIV89.6P. Two weeks after the first stimulation, grow
T-cell clones infected with SHIV89.6P and B-LCLs infected with rVV exp
chromium release assay at E/T ratio of 80/1, 40/1, 20/1, and 10/1. Results shown
spontaneous lysis in these experiments ranged between 49 and 285 and maattributed to the boosting effect of vaccine-II that con-
ferred the long-lasting protection, and this without pro-
ductive infection in PBMCs.
The availability of HS-immortalized autologous CD41 T
cells, in addition to the more traditional approach using
recombinant vaccinia virus-infected B-LCLs for use as
targets in CTL assays, added relevance to the clinical
interpretation of the results. CD41 T cells are one of the
main targets of the pathogenic virus and, when used as
targets after infection with vaccine and challenge vi-
ruses, extended the range of interpretation of the CTL
assays. In view of the high rate of mutation in lentiviruses
during infection, and the presence of different quasispe-
cies of the virus, B cells cannot serve as efficient targets
for detection of CTL responses, except where CTL
epitopes are highly conserved. Since HS-immortalized
CD41 T cells can be infected with different viral quasi-
species, they have been successfully used as targets in
cytotoxicity assays against constantly evolving immune
escape viruses (Stipp et al., 2000). In this study, all four
nimals that were immunized with vaccine virus had
eveloped CTLs to vaccine and challenge viruses prior
o challenge. These CTLs in three of these animals
ecognized the three structural lentiviral proteins, Env,
ag, and Pol, but in one animal, RWg, they recognized
nly Env, not Gag and Pol proteins. Following challenge
ith SHIV89.6P, this animal developed CTL activity against
9.6P, HIV-1ENV, SIV-GAG, and SIV-POL. PBMCs from the four vaccinated
, were stimulated twice with UV-irradiated autologous HS CD41 T-cell
lls were used as CTL effectors and tested against autologous HS CD41
g HIV-1Env, SIV-Gag, and SIV-Pol. The effectors were tested in a 4-ht SHIV8
HIV89.6P
ing ce
ressinhere are specific lysis obtained at an effector/target ratio of 40/1. The
ximal release ranged between 203 and 1462.
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250 KUMAR ET AL.all three proteins, albeit at a low level. The low reactivity
to Gag and Pol proteins could have been responsible for
the relatively higher level of virus replication in this ani-
mal compared to that of the other vaccinates.
Our results also showed that the lymph node CTLs
had a broader range and a higher magnitude of specific
lysis compared to that of the CTLs in PBMCs. This
suggested that measurement of CTL activity in the lymph
nodes was a more accurate correlate of resistance of the
immunized animals to the virus. Comparison of PBMC
and lymph node CTLs is not a common practice. How-
ever, in a recent study in SIV-infected macaques, PBMCs
and lymph nodes showed almost similar patterns of CTL
activity (Kuroda et al., 1999). The reason for the different
pecificity of the CTLs in the two compartments of the
mmune system in this study is not yet known, although
t might be attributed to different precursor frequencies in
he blood and lymph nodes.
This study suggested that neutralizing antibodies
ight have had a lesser role than CTLs in controlling
eplication of the challenge virus. Vaccine-induced anti-
odies neutralized vaccine-I virus but did not neutralize
accine-II. This might be attributed to the fact that vac-
ine-I and vaccine-II Env sequences differed in 2.3%
mino acids, variations that might be critical in expres-
ion of neutralization epitopes. The challenge virus
HIV89.6P Env has 16.7% sequence variation compared to
that of vaccine-I and 18.1% with vaccine-II; therefore,
T
Long-Term CTLs in Macaques Immunized with Vacc
Macaque
Week
postchallenge Cont.b SHIV89
RJo 29 2.2 45.4
52 0 42.3
77 0.2 58.1
RPz 29 1.6 37.3
52 0 27.8
77 2.2 38.5
RTt 29 2.3 36.8
52 0 29.8
77 2.3 47.3
RWg 29 0 58.6
52 0 32.8
77 0 54.5
a PBMC effectors from different animals were tested against different
here are specific lysis obtained at Effector/Target ratio of 40/1. The s
maximal counts ranged between 1473 and 1815.
b Specific lysis against control targets represents either uninfected
accinia virus and used as targets in 4-h chromium release assay.
c Autologous CD41 T-cell clones were infected with SHIV89.6P virus f
d Autologous B-LCLs were infected overnight with recombinant vacci
e Not done.vaccine-induced neutralizing antibodies could not neu-
tralize SHIV89.6P. The neutralizing-antibody responses tothe challenge virus apparently developed only after pro-
ductive infection of the latter; thus, they could not have
had a role in controlling the initial infection by the chal-
lenge virus. However, whether these antibodies had a
role in subsequent elimination of the virus is open to
speculation. Earlier studies in several laboratories in-
cluding ours showed that passive immunization with
neutralizing antibodies could prevent infection with virus
given later, but the antibodies had no effect on early
containment of the virus when administered after inocu-
lation of the virus (Foresman et al., 1998; Shibata et al.,
999; Mascola et al., 1999; Binley et al., 2000). The long-
erm effects of passive immunization on SHIV pathogen-
sis are not known. It is possible that the combined
ffect of the antibodies that emerged following challenge
ith SHIV89.6P and the CTLs may have been responsible
for clearing virus in the challenged animals in the
present study.
This study also confirms earlier observations that de-
velopment of protective antibodies is time dependent
and associated with a complex and lengthy maturation of
immune responses over the first 6 to 8 months postin-
oculation. During this time period, envelope-specific an-
tibody responses undergo an evolution in quantitative
and qualitative properties systems. The completed mat-
uration of immune responses is then characterized by
relatively steady-state antibody responses that are main-
tained indefinitely (Clements et al., 1995; Cole et al.,
llowed by Vaccine-II and Challenged with SHIV89.6P
Percentage specific lysis againsta
HIVEnv
d SIVGag
d SIVPol
d SIVNefd
32.9 47.9 57 NDe
18.6 32.9 36.9 21.1
56.4 54.5 44.3 63.2
25.4 32.5 25.4 NDe
40.2 15 21.4 24.9
55.6 52.9 58.7 55.5
29.8 54.1 46.1 NDe
11.7 41.8 23.5 24.9
44 57.4 47.7 48.8
47.1 42.1 35.7 NDe
17 37.4 87.8 33.1
33.5 59.8 42.9 54.9
at Effector/Target ratio of 80/1, 40/1, 20/1, and 10/1. The results shown
eous counts in these experiments ranged between 187 and 210 and
ous CD41 T-cell clone or autologous B-LCLs infected with wild type
ys, labeled with [51Cr] and used in cytotoxicity assays.
s expressing either HIVEnv, SIVGag, SIVPol, or SIVNef and used as targets.ABLE 4
ine-I Fo
.6P
c
targets
pontan
autolog
or 3 da1997a,b, 1998; Montelaro et al., 1998). After immunization,
vaccine-I- and vaccine-II-specific antibodies required
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251IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSabout 9 months before they attained peak levels and
then maintained at steady levels. Likewise, after chal-
lenge, SHIV89.6P-specific antibodies were produced but
again they required more than 8 months before achiev-
ing peak levels. In a previously reported study, live at-
tenuated SIV has been found to induce SIV-specific an-
tibodies that directly correlated with the level of protec-
tion after challenge with pathogenic SIVMAC251 and
nversely correlated with the level of attenuation of vac-
ine virus (Johnson et al., 1999).
The findings in this report not only clearly suggest that
ignificant protection can be achieved in the absence of
hallenge virus-specific neutralizing antibodies but also
upport a growing consensus that virus-specific CTLs
re one of the most important effector mechanisms re-
ponsible for suppression of virus replication in HIV-1-
nfected individuals and in SIV- or SHIV-infected experi-
ental animals (Harrer et al., 1996; McMichael and
O’Callaghan, 1998; Ogg et al., 1998; Johnson and Desro-
siers, 1998; Wyand et al., 1999; Johnson et al., 1999). The
eminal role of these cells in regulating pathogenesis
as previously well established in SIV-infected ma-
aques, in which their depletion resulted in higher virus
urdens (Schmitz et al., 1999; Jin et al., 1999). The results
FIG. 7. SHIV89.6P-specific CTL activity in macaques immunized with
estricted and mediated by CD81 T lymphocytes. PBMCs from the four v
SHIV89.6P, were stimulated twice with UV-irradiated autologous HS CD4
growing cells were used as CTL effectors and tested against autologo
T-cell clone from another rhesus macaque was used as an allo-target.
described above and used as CTL effectors in a 4-h chromium release
esults shown here are specific lysis obtained at an effector/target rati
aximal lysis between 610 and 2570.escribed in this report also focus attention on CTLs to
ag and Pol for controlling SHIV infection. The vaccinevirus used in the study was derived from nonpathogenic
SHIV that contained the HIV-1 envelope from HXB2 iso-
late, while challenge virus SHIV89.6P contained the enve-
lope of HIV-189.6. Our results that the live attenuated
vaccines used in this study conferred substantial protec-
tion against virus SHIV89.6P, a virus that contains distinct
env but common gag and pol genes, suggest that pro-
tection, mediated through CTLs against the Gag and Pol
proteins, was common between the two viruses.
In summary, a graded course of immunization, first
with more attenuated virus followed by relatively less
attenuated virus may be a way to reduce the replication
of highly effective vaccine viruses and thus reduce the
chances of reversion of vaccine virus into a pathogenic
strain. The safer sequential vaccination procedure in-
duced long-term protection against AIDS caused by het-
erologous virus. The results in the present study provide
evidence for the apparent lack of correlation between
antibody and protection in vaccinated animals, signifi-
cantly reduced virus replication (200- to 60,000-fold) in
vaccinated group compared to that in control animals,
and positive correlation between virus-specific CTLs and
protection. Whether these protected animals develop
e-I, followed by vaccine-II, and challenged with SHIV89.6P was MHC
ed macaques, obtained 12 weeks after challenge with pathogenic virus
ll clones infected with SHIV89.6P. Two weeks after the first stimulation,
allogenic HS CD41 T-cell clones infected with SHIV89.6P. A HS CD4
1
ly selected CD41 and CD81 T cells were stimulated with SHIV89.6P as
against autologous HS CD41 T-cell clones infected with SHIV89.6P. The
/1. The mean spontaneous lysis was between 109 and 475 and meanvaccin
accinat
1 T-ce
us and
Positive
assayprogressive decline of challenge virus DNA as seen in
animals immunized with vaccine-II alone (Silverstein et
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252 KUMAR ET AL.al., 2000) will be determined in follow-up studies in these
animals.
MATERIALS AND METHODS
Viruses
Constructions of vaccine-I and vaccine-II (Joag et al.,
1998a) viruses and derivation of and SHIVKU-2 (Joag et al.,
1998b) were previously described. These viruses were
grown in CEMx174 cells. The challenge virus SHIV89.6P
(Reimann et al., 1996a,b) was kindly provided by Dr.
Norman L. Letvin (Boston, MA) and grown in PHA-stim-
ulated PBMC from a normal healthy monkey. Infectivity of
stocks of the four viruses was assayed in C8166 cell
culture and titers of log 4.2, 4, 4.8, and 4.0 were obtained
for vaccine-I, vaccine-II, SHIVKU-2, and SHIV89.6P, respec-
tively. Herpesvirus papio stock was obtained by growing
the S594 cell line (provided by Dr. N. Letvin). The S594
cell line is an immortalized B-cell line productively in-
fected with the baboon Herpesvirus papio (Rabin et al.,
1977). Herpesvirus saimiri was purchased from ATCC
(Manassas, VA) and stock cultures were prepared by
inoculating monolayer cultures of owl monkey kidney
(OMK) cells as previously described (Kumar et al., 1999).
The recombinant vaccinia viruses that were used to
infect target cells included vAbT299 (expressing
HIV-1BH-10Env lacking 19 amino acids, starting from posi-
tions 42–60 at the amino terminus), vAbT252 (SIVmac251-
Gag), vAbT258R (SIVmac251-Pol), vAbT306 (SIVmac239-
ef), and NYCBH (wild type vaccinia virus). These were
indly provided by Drs. D. Panicali and G. Mazzara (The-
ion Biologics, Cambridge, MA). The recombinant vac-
inia viruses were propagated in HeLa cell cultures. All
irus stocks were maintained at 280°C, except the chal-
enge virus stocks that were stored in liquid nitrogen.
accination of macaques and challenge with SHIV89.6P
Seven 3- to 5-year-old rhesus macaques (Macaca mu-
atta) were obtained from the Yerkes Primate Center
Atlanta, GA) and maintained in the AAALAC-approved
nimal Facility of the University of Kansas Medical Cen-
er. Four of the animals were inoculated subcutaneously,
lose to the inguinal and axillary lymph nodes, with 1 ml
f vaccine-I. Four months later, these four animals re-
eived two doses of 1 ml of vaccine-II, given orally 1 day
part. Since vaccine-I virus was T-cell-tropic, it was ad-
inistered by subcutaneous route. The vaccine-II is dual
ropic and was administered by oral route (results not
hown). Three months following this, the animals were
iven a booster dose of vaccine-II. Thirty weeks after the
hird immunization, the vaccinated and three unvacci-
ated control animals were challenged iv with 1 ml of
ndiluted SHIV89.6P (10
4 TCID50) stock. These animals
1were bled regularly to monitor CD4 T-cell profiles, cell-
associated as well as cell-free viral loads in the blood,and cellular and humoral immune responses to the dif-
ferent viruses.
Flow cytometry
Leukocytes in whole blood collected in EDTA were
analyzed for expression of CD3, CD4, and CD8 cell
surface markers by whole blood lysis technique as pre-
viously described (Wyand et al., 1999). Briefly, 20 ml of
antibody mix against CD3, CD4, and CD8 (Becton–Dick-
inson, Rutherford, NJ) was added to 100 ml of whole
blood and incubated for 30 min in the dark. Lysing
solution (Becton–Dickinson) was then added and the
samples were incubated for another 10 min at room
temperature. Stained cells were fixed with 0.5% parafor-
maldehyde and analyzed in a flow cytometer (Becton–
Dickinson FACS Calibur).
Viral load measurements
Plasma viral RNA levels were determined by real-time
reverse transcriptase–PCR (ABI Prism 7700-sequence
detection system; Perkin–Elmer, Palo Alto, CA) using
reverse-transcribed viral RNA from macaque plasma
samples as templates. Primer sequence and the proce-
dures for RNA extraction, reverse transcription, and PCR
were previously described (Suryanarayana et al., 1998).
The sensitivity of this assay was 100 copies Eq/ml of
plasma. The frequency of infectious cells in blood was
determined by inoculation of serial 10-fold dilutions of
PBMC into cultures of C8166 cells that were then ob-
served for the development of cytopathic effects (CPE)
(Joag et al., 1998a). Results are expressed as the number
of infectious cells per 106 PBMC.
Recovery of infectious virus from PBMCs and lymph
node cells
Two million CD8-depleted PBMCs or lymph node cells
were stimulated with PHA (1 mg/ml) for 2 days in 2 ml
R-10 (RPMI 1640 containing 10% FBS, 5 mM NaHCO3,
and 50 mg/ml gentamicin), after which they were washed
and cultured in R-10/IL-2 (R-10 containing 50 IU/ml re-
combinant interleukin 2) for 5 days. The supernatant
fluids were tested for virus cytopathocity in C8166 cul-
ture.
Detection of viral DNA in PBMC and lymph nodes
Cellular DNA was extracted from PBMCs and lymph
nodes of the four vaccinated animals and used as a
template in nested PCR as previously described (Joag et
al., 1998a). Pathogenic virus was detected by amplifica-
tion of the SHIV89.6P-specific envelope. For the first round
of PCR amplification, we used ES361 (59-GATAGACTA-
ATAGAAAGAGCAGAAGAC-39) and SM-1 (59-GATGAA-
CATCTAATTTGTCCTG-39, antisense), which are comple-
mentary to nts 6305 to 6331 and 7647 to 7669 of the
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253IMMUNE PROTECTION AGAINST SHIV-INDUCED AIDSSHIV89.6P genome. A 0.5-mg sample of genomic DNA was
sed in the 50-ml reaction mixture and amplified for 40
ycles in a hot-start PCR. The reaction conditions were:
7°C for 1 min 45 s, 55°C for 2 min, and 72°C for 5 min
or one cycle; 94°C for 30 s, 55°C for 30 s, and 72°C for
0 s for 38 cycles; and 94°C for 30 s, 55°C for 30 s, and
2°C for 6 min for one cycle. A 2-ml aliquot of the
first-round PCR product was again amplified using SM-2
(59-7168CTGAAGATTTCACAGACAATGT7169-39) and SM-1
primers. The expected size of the nested PCR product
was 501 bp. A 5-ml aliquot of the second-round PCR
product was electrophoresed in a 2% agarose gel and
stained with ethidium bromide for visualization. This as-
say is capable of detecting one viral genome in approx-
imately 104 cells.
Determination of binding antibodies against vaccine
and challenge viruses
Sequentially collected plasma samples from vacci-
nated macaques were analyzed for the presence of bind-
ing antibodies to native viral glycoprotein using Con A
ELISA originally developed by Robinson and coworkers
(1990) and adapted to the SIV and SHIV systems by
Montelaro and coworkers (Cole et al., 1997a,b, 1998).
riefly, purified virus was treated with Triton X-100 and
sed as viral antigens. Immulon-2 plates were coated
ith Con A followed by the addition of total viral proteins.
he reactivity was detected by the addition of 1/10,000
ilution of HRP-labeled anti-monkey IgG followed by re-
ction with ortho-phenylinediamine (OPD).
etermination of neutralizing antibodies against
accine viruses
Neutralizing antibody titers in the plasma were deter-
ined by adding serial twofold dilutions of heat-inacti-
ated plasma, prepared in R-10 to flat-bottom 96-well
lates, using four wells per dilution. Eight TCID50 of
vaccine-I, vaccine-II, or SHIV89.6P viruses were then
added to each well and the plates were incubated at
37°C for 1 h, followed by addition of 104 C8166 cells to
each well. After 1 week of incubation at 37°C, each well
was scored for CPE (Kumar et al., 2000).
Development of B-lymphoblastoid cell line (B-LCL)
The B-lymphoblastoid cell lines (B-LCLs) were derived
by inoculating PBMCs with Herpesvirus papio and main-
taining the cells for 2 weeks in the presence of 500 ng/ml
of cyclosporin-A (Sigma, St. Louis, MO) in 200 ml of R-10.
Proliferating cells were transferred to tissue culture
flasks and maintained in R-10 throughout the study (Ku-
mar et al., 2000).
Development of autologous CD41 T-cell clones
1CD4 T cells from all animals were immortalized by
infection with Herpesvirus saimiri. Briefly, CD8-depletedPBMCs were inoculated with Herpesvirus saimiri and
aintained in R-10/IL-2 for 1 week. The cells were then
loned by the limiting dilution method, using irradiated
uman PBMCs as feeders. Proliferating clones were
ultured in R-10/IL-2 and characterized by the expression
f the CD4 cell surface marker (Kumar et al., 1999).
Generation of effector T-cell populations and CTL
assays
Effectors for the CTL assays were obtained by cocul-
turing PBMCs from vaccinated and control macaques
with UV-irradiated, autologous Herpesvirus saimiri-im-
mortalized CD41 T cells (HS-CD41 T cells) infected with
either vaccine-II virus or SHIV89.6P as previously de-
scribed (Kumar et al., 1999). After 3 days, the medium
was supplemented with recombinant interleukin 2 (rIL-2).
On Day 7, growing PBMCs were restimulated with similar
stimulators and maintained in R-10/IL-2. These effectors
were used in chromium-release assays 6–9 days after
restimulation and tested against virus-infected targets
and recombinant vaccinia virus-infected targets. Autolo-
gous HS-CD41 T cells infected with either SHIVKU-2 or
SHIV89.6P were infected for 3 days and used as virus-
specific targets. In a typical experiment 50–70% of the
CD41 T cells were infected with different viruses (results
not shown). Autologous B-LCLs were infected overnight
with recombinant vaccinia viruses expressing HIV-1Env,
SIV-Gag, SIV-Pol, or SIV-Nef and used as targets in chro-
mium-release assays.
Target cells, labeled with 100 mCi 51Cr [spec. act. 962
MBq/ml of sodium chromate; (Amersham, Cleveland,
OH)], were dispensed into 96-well V-bottom plates, and
effector cells were tested in triplicate at effector/target
(E/T) ratios of 80/1, 40/1, 20/1, 10/1, and 5/1. Chromium
release was determined after a 4-h incubation at 37°C by
counting 100 ml supernatant from each well in a Gamma
counter (Packard Instruments, Meriden, CT). Each exper-
iment had three wells containing 2500 respective targets
in medium that provided data for spontaneous lysis,
while three wells containing targets and 100 ml of 1%
SDS provided data for maximal lysis. The percentage
specific lysis was calculated as: (mean CPM in test
wells 2 mean CPM in spontaneous wells)/(mean CPM in
maximal wells 2 mean CPM in spontaneous wells) 3
100.
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